We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+29.27%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$363M
AUM Growth
+$103M
Cap. Flow
+$92.4M
Cap. Flow %
25.45%
Top 10 Hldgs %
73.47%
Holding
43
New
11
Increased
12
Reduced
5
Closed
12

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$20M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$19.2M
3
VNDA icon
Vanda Pharmaceuticals
VNDA
+$15.5M
4
CLDX icon
Celldex Therapeutics
CLDX
+$9.33M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$8.63M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$17.2M
2
EBS icon
Emergent Biosolutions
EBS
+$9.51M
3
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$7.59M
4
STML
Stemline Therapeutics, Inc.
STML
+$6.87M
5
QURE icon
uniQure
QURE
+$5.51M

Sector Composition

Rank Sector Weight
1 Healthcare 86.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRIL
26
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.06M 0.57%
94,400
-66,297
-41% -$1.51M
SCPX
27
DELISTED
Scorpius Holdings, Inc.
SCPX
$2.01M 0.55%
1
– –
BIIB icon
28
Biogen
BIIB
$30B
$1.82M 0.5%
+4,500
New +$1.81M
GYRE icon
29
Gyre Therapeutics
GYRE
$641M
$1.64M 0.45%
746
+154
+26% +$309K
CLLS
30
Cellectis
CLLS
$277M
$1.08M 0.3%
30,000
– –
XNTK icon
31
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.06B
$770K 0.21%
+700,000
New +$36.2M
CRDF icon
32
Cardiff Oncology
CRDF
$66.5M
– –
-4,496
Closed -$2.21M
EBS icon
33
Emergent Biosolutions
EBS
$373M
– –
-330,635
Closed -$9.51M
QURE icon
34
uniQure
QURE
$3.03B
– –
-226,456
Closed -$5.51M
SGMO
35
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-244,199
Closed -$3.83M
TXMD icon
36
TherapeuticsMD
TXMD
$23.5M
– –
-7,840
Closed -$2.37M
ALIM
37
DELISTED
Alimera Sciences
ALIM
– –
-5,425
Closed -$408K
TARO
38
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
– –
-53,800
Closed -$7.59M
BIOL
39
DELISTED
Biolase, Inc.
BIOL
– –
-55
Closed -$1.39M
CCXI
40
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-323,607
Closed -$2.44M
STML
41
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-475,000
Closed -$6.87M
RXDX
42
DELISTED
Ignyta, Inc.
RXDX
– –
-200,772
Closed -$2M
CELG
43
DELISTED
Celgene Corp
CELG
– –
-148,800
Closed -$17.2M
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q2 2015 Portfolio in Review

As of Q2 2015, Avoro Capital Advisors held 43 positions worth $363M, up 39% from $261M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Avoro Capital Advisors deployed $92.4M of net new capital in Q2 2015, opening 11 new positions and adding to 12 existing holdings. Its largest new stake was Acadia Pharmaceuticals: 495,000 shares worth $20.7M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 84% a quarter earlier.

On the sell side, the largest reduction was Bellicum Pharmaceuticals, Inc., an estimated $5.21M trimmed.

  • Avoro Capital Advisors's largest Q2 2015 buy was Acadia Pharmaceuticals: 495,000 shares worth $20.7M.
  • Avoro Capital Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q2 2015, an estimated $20M increase.
  • Avoro Capital Advisors's biggest Q2 2015 reduction was Bellicum Pharmaceuticals, Inc., cutting an estimated $5.21M.
  • Avoro Capital Advisors fully exited Celgene Corp in Q2 2015, selling an estimated $17.2M.
  • Avoro Capital Advisors's ten largest holdings make up 73% of its $363M portfolio in Q2 2015.
  • Avoro Capital Advisors opened 11 new positions and closed 12 in Q2 2015.
  • Avoro Capital Advisors's portfolio value rose 39% quarter-over-quarter to $363M.

Based on Avoro Capital Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.